Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals
- PMID: 35513787
- PMCID: PMC9074271
- DOI: 10.1186/s12886-022-02432-9
Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals
Abstract
Background: Presbyopia is a common progressive vision disorder characterised by an inability to focus on near objects. The emergence of newer treatment options in addition to spectacles or contact lenses highlights the importance of assessing patient/user preferences.
Methods: People with presbyopia and healthcare professionals (HCPs) took part in a moderated, structured discussion of specific questions on a virtual advisory-board platform. The objective was to better understand unmet needs and the experience of living with the condition. Closed and open questions were included.
Results: Nine individuals (age 40 to 70 years) with presbyopia participated, from Australia, China, France, Italy, Ireland, Japan and the US. One ophthalmologist and one optometrist represented the perspective of HCPs. Over two weeks, 621 posts were entered on the platform. There was widespread agreement that the often stated association between age and presbyopia was unfortunate. Some participants had developed presbyopia at 30-45 years of age. What is more, the association with age was seen as implying a natural process, reducing the incentive to treat. Instead there was a call for an action-oriented view of presbyopia as a condition which may be effectively treated in the future. All participants experienced dealing with presbyopia as burdensome, affecting quality of life to varying degrees. When considering new treatments, convenience was the most important factor. The option to administer drops when needed was considered favourable, but short-acting treatments may not reduce inconvenience compared with spectacles. Participants viewed a therapy that targets the underlying cause of the condition favourably compared with symptomatic treatment. Side effects would severely reduce the appeal of drops. For clinical trials in presbyopia, patient-reported outcomes should be mandatory and need adequately to capture quality of life. Studies in presbyopia must be designed to minimise the inconvenience to participants in order to counter the risk of high drop-out rates.
Conclusions: The interactive format provided insights into living with presbyopia, particularly the negative impact on quality of life, subjects' openness to new therapies, and the need to move away from considering the condition an unavoidable and intractable consequence of ageing.
Keywords: Clinical trials; Interactive dialogue; Mode of action; Patient life experience; Unmet need.
Plain language summary
The term presbyopia describes the difficulty to focus the eyes on things nearby, due to stiffening of the eye lens. The condition often considered something which worsens with increasing age. Many people cope with presbyopia by wearing reading glasses or bifocals, but alternative treatments are being developed. This publication reports from a moderated discussion among people with presbyopia and healthcare professionals specialising in eye health. People with presbyopia strongly felt that it should not be seen as an inevitable effect of middle age, but as something which may be treated medically. They felt that reading glasses, bifocals and monovision lenses were a daily burden and did not fit with how they wanted to live their lives. When discussing possible medical treatments, the option to use drops instead of glasses to improve eye sight appealed to the participants, particularly if the drops acted on the mechanism behind the stiffened lens with effect over many weeks or months. Convenience was the key benefit the participants would look for when considering a new treatment. Importantly, drops must not have any undesirable effects such as burning. The roundtable discussion showed the need for both healthcare professionals and those living with presbyopia to take the condition seriously with an an action-oriented view towards better therapies in the future.
© 2022. The Author(s).
Conflict of interest statement
MB reports speaker or advisory board honoraria or research support from ABB Optical, Alcon Laboratories, Allergan, Art Optical, Bausch + Lomb Health, Contamac, CooperVision, CSEye, Horizon Therapeutics, Johnson & Johnson Vision Care, Kala, Lenstech, Novartis, Optovue, Oyster Point, RVL, Sun Pharma, Tarsus, Tangible Science, Thea, Santen, Walman Optical and Zea Vision. JT is President and CEO of Prevent Blindness, an organisation which has received support from Novartis in the past for projects unrelated to the current work. EB, MW and FP are employees of Novartis; JA and PK report no conflict of interest.
Figures



Similar articles
-
Exploring the Experience of Living with and Managing Presbyopia.Optom Vis Sci. 2022 Aug 1;99(8):635-644. doi: 10.1097/OPX.0000000000001913. Epub 2022 Jun 9. Optom Vis Sci. 2022. PMID: 35678617
-
Exploring contact lens opportunities for patients above the age of 40 years.Cont Lens Anterior Eye. 2022 Dec;45(6):101599. doi: 10.1016/j.clae.2022.101599. Epub 2022 Apr 16. Cont Lens Anterior Eye. 2022. PMID: 35440406
-
[TREATMENTS FOR PRESBYOPIA].Harefuah. 2022 Jul;161(7):448-453. Harefuah. 2022. PMID: 35833432 Review. Hebrew.
-
Patient Perception and Self-Reported Outcomes with Presbyopia-Correcting Intraocular Lenses (PCIOLs): A Social Media Listening Study.Ophthalmol Ther. 2024 Jan;13(1):287-303. doi: 10.1007/s40123-023-00840-8. Epub 2023 Nov 10. Ophthalmol Ther. 2024. PMID: 37948016 Free PMC article.
-
Presbyopia: Effectiveness of correction strategies.Prog Retin Eye Res. 2019 Jan;68:124-143. doi: 10.1016/j.preteyeres.2018.09.004. Epub 2018 Sep 19. Prog Retin Eye Res. 2019. PMID: 30244049 Review.
Cited by
-
Living with food allergies: the experiences of adult patients and caregivers.Front Allergy. 2023 Nov 6;4:1272851. doi: 10.3389/falgy.2023.1272851. eCollection 2023. Front Allergy. 2023. PMID: 38026132 Free PMC article.
-
Understanding Perspectives on Presbyopia and Use of Pilocarpine HCl 1.25% Twice Daily from Participants of the Phase 3 VIRGO Study.Ophthalmol Ther. 2024 Jun;13(6):1723-1742. doi: 10.1007/s40123-024-00935-w. Epub 2024 Apr 25. Ophthalmol Ther. 2024. PMID: 38662193 Free PMC article.
-
Living with Elevated Lipoprotein(a) Levels: The Experiences of Patients and Caregivers.Patient Prefer Adherence. 2025 Feb 21;19:395-405. doi: 10.2147/PPA.S478623. eCollection 2025. Patient Prefer Adherence. 2025. PMID: 40008374 Free PMC article.
References
-
- Stevens MA, Bergmanson JP. Does sunlight cause premature aging of the crystalline lens? J Am Optom Assoc. 1989;60:660–663. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous